90. Retinitis pigmentosa Clinical trials / Disease details

Clinical trials : 130 / Drugs : 180 - (DrugBank : 41) / Drug target genes : 49 - Drug target pathways : 109

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04864496 (ClinicalTrials.gov)	April 17, 2021	21/4/2021	Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa	Effects of Oral N- Acetylcysteine on Macular Function in Retinitis Pigmentosa; a Phase 2 Randomized Controlled Trial	Retinitis Pigmentosa	Drug: Prescribe N-acetylcysteine tablets;Drug: Prescribe placebo tablets	Shahid Beheshti University of Medical Sciences	NULL	Active, not recruiting	18 Years	40 Years	All	30	Phase 2	Iran, Islamic Republic of
2	NCT03999021 (ClinicalTrials.gov)	June 24, 2019	24/6/2019	FIGHT-RP 1 Extension Study	A Phase 1 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa	Retinitis Pigmentosa	Drug: NAC effervescent tablets	Johns Hopkins University	NULL	Active, not recruiting	18 Years	N/A	All	30	Phase 1	United States
3	NCT03063021 (ClinicalTrials.gov)	February 15, 2017	16/2/2017	The FIGHT-RP1 Study	A Phase 1 Open Label Dose Ranging Study to Assess the Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa (FIGHT-RP1 Study)	Retinitis Pigmentosa	Drug: N-Acetyl Cysteine (NAC)	Johns Hopkins University	NULL	Completed	18 Years	N/A	All	30	Phase 1	United States